<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP
        </div>
        <div class="card-body">
                <p>Upregulation of HER2/ErbB2/Neu occurs in 15-30% of human breast cancers and correlates with poor prognosis. Identification of ErbB2/Neu transcriptional targets should facilitate development of novel therapeutic approaches. Development of breast cancer is a multistep process; thus, to identify the transcriptomes associated with different stages of progression of tumorigenesis, we compared expression profiles of mammary tumors and preneoplastic mammary tissue from MMTV-Neu transgenic mice to expression profiles of wild-type mammary glands using Affymetrix microarrays. We identified 324 candidate genes that were unique to ErbB2/Neu-induced tumors relative to normal mammary gland tissue from wild-type controls. Expression of a subset of these genes (82) was also changed in the preneoplastic mammary glands compared to wild-type controls, indicating that they may play a pivotal role during early events of ErbB2/Neu-initiated mammary tumorigenesis. Further analysis of the microarray data revealed that expression of several known transforming growth factor (TGF)-beta target genes was altered, suggesting that the TGF-beta signaling cascade is downregulated in ErbB2/Neu-induced tumors. Western blot analysis for TGF-beta-Receptor-I/ALK5 and immunohistochemistry for TGF-beta-Receptor-I/ALK5 and phosphorylated/activated Smad2 confirmed that the Smad-dependent TGF-beta signaling cascade was inactive in these tumors. Although absent in most of the tumor, phosphorylated Smad2 was present in the periphery of tumors. Interestingly, presence of phosphorylated/activated Smad2 correlated with expression of Activin-Receptor-IB/ALK4, suggesting that although Smad-dependent TGF-beta signaling is absent in ErbB2/Neu-induced tumors, Activin signaling may be active at the leading edge of these tumors. Cumulatively, these data indicate that the TGF-beta pathway is intrinsically suppressed in ErbB2/Neu tumors via a mechanism involving loss of TGF-beta-Receptor-I/ALK5.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M15209">M15209</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:10090">NCBITaxon:10090</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:2115">ncbigene:2115</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1111">ncbigene:1111</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6241">ncbigene:6241</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3783">ncbigene:3783</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1796">ncbigene:1796</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:7163">ncbigene:7163</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:255743">ncbigene:255743</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:58527">ncbigene:58527</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:349633">ncbigene:349633</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:80148">ncbigene:80148</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9455">ncbigene:9455</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:51186">ncbigene:51186</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6500">ncbigene:6500</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2182">ncbigene:2182</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3732">ncbigene:3732</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3398">ncbigene:3398</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1829">ncbigene:1829</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:391059">ncbigene:391059</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3934">ncbigene:3934</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M15209&#39;, name=&#39;LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP&#39;), definition=&#39;Upregulation of HER2/ErbB2/Neu occurs in 15-30% of human breast cancers and correlates with poor prognosis. Identification of ErbB2/Neu transcriptional targets should facilitate development of novel therapeutic approaches. Development of breast cancer is a multistep process; thus, to identify the transcriptomes associated with different stages of progression of tumorigenesis, we compared expression profiles of mammary tumors and preneoplastic mammary tissue from MMTV-Neu transgenic mice to expression profiles of wild-type mammary glands using Affymetrix microarrays. We identified 324 candidate genes that were unique to ErbB2/Neu-induced tumors relative to normal mammary gland tissue from wild-type controls. Expression of a subset of these genes (82) was also changed in the preneoplastic mammary glands compared to wild-type controls, indicating that they may play a pivotal role during early events of ErbB2/Neu-initiated mammary tumorigenesis. Further analysis of the microarray data revealed that expression of several known transforming growth factor (TGF)-beta target genes was altered, suggesting that the TGF-beta signaling cascade is downregulated in ErbB2/Neu-induced tumors. Western blot analysis for TGF-beta-Receptor-I/ALK5 and immunohistochemistry for TGF-beta-Receptor-I/ALK5 and phosphorylated/activated Smad2 confirmed that the Smad-dependent TGF-beta signaling cascade was inactive in these tumors. Although absent in most of the tumor, phosphorylated Smad2 was present in the periphery of tumors. Interestingly, presence of phosphorylated/activated Smad2 correlated with expression of Activin-Receptor-IB/ALK4, suggesting that although Smad-dependent TGF-beta signaling is absent in ErbB2/Neu-induced tumors, Activin signaling may be active at the leading edge of these tumors. Cumulatively, these data indicate that the TGF-beta pathway is intrinsically suppressed in ErbB2/Neu tumors via a mechanism involving loss of TGF-beta-Receptor-I/ALK5.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;15897883&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;10090&#39;, name=&#39;Mus musculus&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2115&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1111&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6241&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3783&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1796&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7163&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;255743&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;58527&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;349633&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;80148&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9455&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;51186&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6500&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2182&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3732&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3398&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1829&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;391059&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3934&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C2&#39;], &#39;sub_category_code&#39;: [&#39;CGP&#39;], &#39;contributor&#39;: [&#39;Leona Saunders&#39;], &#39;exact_source&#39;: [&#39;Table 2: Increased in adjacent erbB2/neu samples&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>